SCHEMBL1686499

SCHEMBL1686499

CCCc1ccc([Si](O)(O)c2ccc(CCC)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.50
LIPG Q9Y5X9 1/20 0.50
PLK1 P53350 1/20 0.44
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
THRB P10828 2/20 0.42
CA2 P00918 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MGLL Q99685 1/20 0.39
POLB P06746 2/20 0.39
CTDSP1 Q9GZU7 2/20 0.39
KDM4E B2RXH2 2/20 0.39
NISCH Q9Y2I1 1/20 0.39
HTR1D P28221 1/20 0.39
GAA P10253 1/20 0.39
ESR1 P03372 2/20 0.39
ADRA2A P08913 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
TACR2 P21452 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1686652 0.86 CA2 (0.53) LPLLIPGPLK1THRBCA2
SCHEMBL1686822 0.85 ESR1 (0.59) LPLLIPGALDH1A1MGLLKDM4E
SCHEMBL1686688 0.83 ESR1 (0.62) LPLLIPGALDH1A1MGLLKDM4E
SCHEMBL1686414 0.83 ESR1 (0.62) LPLLIPGALDH1A1MGLLKDM4E
SCHEMBL1686669 0.83 ESR1 (0.62) LPLLIPGALDH1A1MGLLKDM4E
SCHEMBL1686607 0.83 ESR1 (0.62) LPLLIPGALDH1A1MGLLKDM4E
SCHEMBL1687093 0.83 ESR1 (0.62) LPLLIPGALDH1A1MGLLKDM4E
SCHEMBL1686679 0.80 CYP2A6 (0.46) LPLLIPGPLK1L3MBTL1ALDH1A1
SCHEMBL142480 0.79 LPL (0.62) LPLLIPGPLK1CNR1CNR2
SCHEMBL3264156 0.78 LPL (0.46) LPLLIPGPLK1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932330-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-7592402-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-09-22 US disclosed
US-20080319148-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2008-12-25 US disclosed
US-7115539-B2 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
US-20050245701-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2005-11-03 US disclosed
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer AP1M1, PYM1, SEM1 LPL 4606/4885LIPG 4621/4885PLK1 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.